Intodna S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2020-12-31
Share capital
108,130.10 PLN
Activity description

Intodna offers DNA damage detection and analysis of DNA repair biology using the STRIDE® platform. The company provides single-cell resolution and AI-driven data analysis. It serves pharmaceutical companies, biotechs, and research laboratories.

Registered address
ul. Profesora Michała Bobrzyńskiego 14, 30-348 Kraków, Poland
Email
Social media
Electronic delivery address
AE:PL-88449-56008-EISEV-23

Financials

Revenue history (in k)

Financial insight

  • The statement flags a going concern risk. Opis znajduje się w Informacji Dodatkowej w nocie nr 19 "Informacja dotycząca założenia kontynuacji działalności"

Filing timeliness

3 of 5 financial statements were filed late (the longest delay 101 days for 2021). All were audited by a statutory auditor.

  • 202508/07/2026
  • 202408/07/2025
  • 202305/08/2024
  • 202228/07/2023
  • 202124/10/2022
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 14%
Top 8.4%
City · Kraków2,402 / 16,222
Top 15%
Voivodeship · Małopolskie5,102 / 27,818
Top 18%
Country · Poland56,420 / 298,026
Top 19%

Results vs industry

Revenue
This companyUSD 2.29mMedianUSD 154.14kAverageUSD 4.79m
Net profit
This companyUSD -537.28kMedianUSD -276.14AverageUSD 308.69k
Operating costs
This companyUSD 2.65mMedianUSD 188.95kAverageUSD 4.61m
Assets
This companyUSD 2.83mMedianUSD 283.11kAverageUSD 8.34m

Offer

  • DNA damage detection
  • Functional DNA repair assays
  • Laboratory assay development
  • Biomarker development
  • Confocal imaging
  • Biological data analysis

Websites

  • intodna.comWhere DNA Breaks, Our Insight Begins – intoDNA
    WordPress 7.1Google Tag ManagerYoast SEOCloudflareLiteSpeed

Job offers

The company lists 3 job openings on its own careers page: intodna.com/careers.

Position
Data Scientist (Predictive Modelling)
Business development director, CDx and pharma services
Senior scientist

Authorized Representatives

Agata Wierzbicka age 40 – Management Board Member
Bartłomiej Kiszala age 42 – Management Board Member
Kamil Solarczyk age 40 – Management Board Member
Magdalena Kordon-Kiszala age 39 – President of the Management Board

Manner of representation

Each member of the management board acting independently is authorised to submit declarations of will concerning property rights and obligations and to sign on behalf of the company, provided that joint action by two members of the management board acting jointly is required to incur obligations or dispose of a right in an amount equal to or exceeding PLN 250,000.00 (two hundred and fifty thousand zlotys).

Supervisory board

Krzysztof Langer age 41 – Supervisory Board Member
Maciej Zajda age 42 – Supervisory Board Member
Mateusz Stankiewicz age 41 – Supervisory Board Member

Beneficial owners

Person

Sanctions and PEP

Sanctions

No matches (EU, UN, US, UK, MSWiA, World Bank)

PEP

No matches

Bank accounts

Registered as a VAT taxpayer on 2017-12-22.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

10 public aid cases recorded, with a total value of $2,347,134.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$306K
Regional investment aid
$258.1K
De minimis aid (in accordance with Commission Regulation 2023/2831)
$8,018

European Funds

ProjectEU co-financing
Development and implementation of a new method for the direct detection and measurement of replication stress in human cells and tissues
$1.6M
Investment in expanding the laboratory infrastructure of INTODNA S.A. to carry out R&D work aimed at developing a new diagnostic technology for identifying and measuring phenomena occurring during DNA replication
$562.9K
Implementation of research and development work to commence providing clinical research support services for new cancer therapies.
$207.1K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Sieć Badawcza Łukasiewicz - Krakowski Instytut Technologiczny Research institute
Energotest sp. z o.o.
Ultrarent sp. z o.o.
Baltictest sp. z o.o.
Aslab Science P.S.A.
Scope Fluidics S.A.
Alcid sp. z o.o.
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Nanogroup S.A.
Precisionlife Poland sp. z o.o.

Change history

DateEvent
2026-05-05Share capital increase
2025-09-05Share capital increase
2020-12-31Entered in the register

FAQ

Last updated: 2026-07-15